Business Description
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -5.64
Total Equity: $9.23M
Shares: 3,210,779
Total Debt: $934,359
Cash: $109,091
EBITDA: -$15.90M
Total Debt: $934,359
Cash: $109,091
Revenue: $0.00
Shares: 3,210,779
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $9.23M
Tax Rate: 0.0%
Equity: $9.23M
Total Debt: $934,359
Cash: $109,091
Current Liabilities: $14.15M
Long-Term Debt: $0.00
Total Debt: $934,359
Total Equity: $9.23M
Shares: 3,210,779
Shares: 3,210,779
CapEx: $4.00
Shares: 3,210,779
Stock Price: $0.28
Net Income: -$18.31M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 11:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $1.2M | $1.3M | $1.3M | $0 |
| Cost of Revenue | $976,454 | $929,441 | $1.0M | $1.1M | $158,831 |
| Gross Profit | $414,518 | $272,728 | $238,188 | $267,829 | $-158,831 |
| Operating Expenses | $9.2M | $9.1M | $16.0M | $5.2M | $7.8M |
| Operating Income | -$8.8M | -$8.8M | -$15.8M | -$4.9M | -$8.0M |
| Net Income | -$9.1M | -$11.9M | -$16.7M | -$7.9M | -$18.3M |
| EBITDA | -$8.5M | -$7.9M | -$15.0M | -$5.2M | -$15.9M |
| EPS | $-1.09 | $-1.36 | $-1.59 | $-8.44 | $-5.64 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 11:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $807,538 | $2.0M | $285,400 | $2.9M | $109,091 |
| Total Current Assets | $1.2M | $2.4M | $850,867 | $3.2M | $1.5M |
| Total Assets | $10.2M | $19.8M | $20.6M | $21.0M | $23.4M |
| Current Liabilities | $4.4M | $3.6M | $6.8M | $13.9M | $14.1M |
| Long-Term Debt | $2.8M | $4.6M | $6.4M | $0 | $0 |
| Total Liabilities | $7.2M | $8.6M | $13.2M | $13.9M | $14.2M |
| Total Equity | $3.1M | $11.2M | $7.4M | $7.1M | $9.2M |
| Retained Earnings | -$51.1M | -$63.1M | -$79.8M | -$87.7M | -$105.9M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 11:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M | -$7.0M | -$6.5M | -$5.0M | -$5.0M |
| Capital Expenditure | $-17,502 | $-1,749 | $-22,159 | $0 | $4 |
| Free Cash Flow | -$5.0M | -$7.0M | -$6.5M | -$5.0M | -$5.0M |
| Acquisitions (net) | $-40,301 | $-51,999 | $0 | $-100,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $80,961 | $1.2M | -$1.7M | $2.6M | -$2.5M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 2:23am (6h ago)| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue |
$1.2M $1.2M – $1.2M
|
$2.4M $2.4M – $2.4M
|
$3.6M $3.6M – $3.6M
|
| EBITDA |
-$1.2M -$1.2M – -$1.2M
|
-$2.4M -$2.4M – -$2.4M
|
-$3.6M -$3.6M – -$3.6M
|
| Net Income | $0 | $0 | $0 |
| EPS | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 11:27pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -13.6% | +4.5% | +6.2% | -100.0% |
| Gross Profit Growth | -34.2% | -12.7% | +12.4% | -159.3% |
| Operating Income Growth | +0.5% | -79.2% | +68.7% | -62.0% |
| Net Income Growth | -31.2% | -40.0% | +52.7% | -131.7% |
| EBITDA Growth | +6.7% | -90.5% | +65.6% | -207.8% |
Narrative Economics
market-narrative step).